This observational study investigates the efficacy and safety of immunoadsorption versus plasmapheresis in 60 patients with relapse in Multiple Sclerosis and Clinically isolated syndrome who do not fully recover after a high doses of intravenous corticosteroids.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
61
Department of Neurology, University of Ulm
Ulm, Baden-Wurttemberg, Germany
Multiple Sclerosis Functional Composite (MSFC)
Time frame: 4 weeks
Expanded Disability Status Scale (EDSS)
Time frame: 2 and 4 weeks
EuroQol (EQ5D-5L)
Time frame: 2 and 4 weeks
Response Rate
defined as share of patients who show an improvement of least 10% in MSFC (see Outcome 1) compared to baseline value
Time frame: 4 weeks
Vision
defined as percentage of normal vision as measured by visual test according to EDSS standardized testing (see outcome 2)
Time frame: 4 weeks
Visually Evoked Potentials (VEP; P100 latency)
Time frame: 4 weeks
Somatosensory Evoked Potentials (SEP; Medianus and Tibialis; N20-, P40-latency)
Time frame: 4 weeks
Thickness of Retinal Nerve Fiber Layer (RNFL) in Optical Coherence Tomography (OCT)
Time frame: 4 weeks
Verbaler Lern- und Merkfähigkeitstest (VLMT) score
Time frame: 4 weeks
MSFC
Time frame: 2 weeks
Thickness of Ganglion Cell Layer (GCL) in OCT
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Symbol Digit Modalities Test (SDMT) score
Time frame: 4 weeks